LYRA vs. MGRM, MBOT, FONR, NTRB, SRTS, INO, TELA, NSPR, MLSS, and VANI
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Monogram Orthopaedics (MGRM), Microbot Medical (MBOT), FONAR (FONR), Nutriband (NTRB), Sensus Healthcare (SRTS), Inovio Pharmaceuticals (INO), TELA Bio (TELA), InspireMD (NSPR), Milestone Scientific (MLSS), and Vivani Medical (VANI). These companies are all part of the "medical equipment" industry.
Lyra Therapeutics vs. Its Competitors
Lyra Therapeutics (NASDAQ:LYRA) and Monogram Orthopaedics (NASDAQ:MGRM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.
Lyra Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, Monogram Orthopaedics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.
Lyra Therapeutics presently has a consensus price target of $100.00, suggesting a potential upside of 743.88%. Monogram Orthopaedics has a consensus price target of $5.40, suggesting a potential upside of 105.32%. Given Lyra Therapeutics' higher probable upside, equities analysts plainly believe Lyra Therapeutics is more favorable than Monogram Orthopaedics.
In the previous week, Lyra Therapeutics had 5 more articles in the media than Monogram Orthopaedics. MarketBeat recorded 6 mentions for Lyra Therapeutics and 1 mentions for Monogram Orthopaedics. Monogram Orthopaedics' average media sentiment score of 1.89 beat Lyra Therapeutics' score of 1.01 indicating that Monogram Orthopaedics is being referred to more favorably in the news media.
Monogram Orthopaedics has lower revenue, but higher earnings than Lyra Therapeutics. Monogram Orthopaedics is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Monogram Orthopaedics shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by insiders. Comparatively, 28.1% of Monogram Orthopaedics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Monogram Orthopaedics has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,635.76%. Lyra Therapeutics' return on equity of -125.07% beat Monogram Orthopaedics' return on equity.
Lyra Therapeutics received 21 more outperform votes than Monogram Orthopaedics when rated by MarketBeat users. However, 60.00% of users gave Monogram Orthopaedics an outperform vote while only 55.81% of users gave Lyra Therapeutics an outperform vote.
Summary
Monogram Orthopaedics beats Lyra Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LYRA) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy LYRA Stock Free LYRA Stock Alerts